Medtronic has issued a recall for several aortic root cannula devices due to a potential safety risk that could cause loose ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Medtronic's stock has lost around a third of its value since late 2022. However, stock prices for longtime dividend growers ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Parkinson's disease patients and advocates are marking Friday as the start of a new era for treatment of the illness as a ...

Medtronic has reported late-breaking ... offer a “less” invasive alternative to traditional open-heart surgery. These two devices have been assessed in over 12 clinical trials.

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...